Biofrontera

Biofrontera Equity Ratio

The Equity Ratio of Biofrontera (B8FK.DE) as of Nov 21, 2026 is 72.20 %. In the previous year, Equity Ratio was 62.54 % — a change of 15.46% (higher).

Equity Ratio

72.20 %

YoY

15.46%

Last updated:

Equity Ratio of Biofrontera is 2025 72.20 % . Equity Ratio of Biofrontera was 2024 62.54 % . It decreases by 15.46% higher compared to the previous year.

The Biofrontera Equity Ratio history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity Ratio
Date
Equity Ratio
Jan 1, 2018
41.80 EUR
Jan 1, 2019
17.06 EUR
Jan 1, 2020
13.08 EUR
Jan 1, 2021
75.43 EUR
Jan 1, 2022
62.14 EUR
Jan 1, 2023
65.01 EUR
Jan 1, 2024
62.54 EUR
Jan 1, 2025
72.20 EUR
The Biofrontera Equity Ratio history
YEAREquity RatioYoY
72.20 %+15.46%
62.54 %-3.81%
65.01 %+4.62%
62.14 %-17.62%
75.43 %+476.79%
13.08 %-23.33%
17.06 %-59.19%
41.80 %+145.36%
17.03 %-74.32%
66.34 %-231.02%
-50.63 %+33,683.53%
-0.15 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biofrontera Stock analysis

What does Biofrontera do? Biofrontera AG generates revenue by developing, selling, and distributing dermatological drugs and medical cosmetics for skin care, protection, and treatment. The company markets its portfolio which includes Ameluz for the photodynamic therapy of actinic keratoses, the PDT lamp BF-RhodoLED used in conjunction with Ameluz treatment, and Belixos, a herbal dermatological cream for conditions such as insect bites, burns, neurodermatitis, and psoriasis. These products address the needs of patients and healthcare providers seeking treatments for skin diseases and regenerative care of damaged skin. The firm also engages in the clinical development of drug candidates to expand its future revenue streams. This includes BF-derm1, a tablet containing an inhibitor that blocks histamine synthesis to prevent allergic reactions, and BF1, a selective serotonin receptor agent aimed at preventing migraines. Through its five wholly owned subsidiaries, notably B, Biofrontera AG supports these development and distribution activities from its headquarters in Leverkusen, Nordrhein-Westfalen. Biofrontera is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biofrontera stock

Equity Ratio of Biofrontera is 72.20 % in 2025.

Equity Ratio of Biofrontera changed from 62.54 % to 72.20 %, representing a 15.46% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Equity Ratio Biofrontera since 2006 – with annual values, charts, and detailed analysis.

The equity ratio measures the proportion of total assets financed by shareholders' equity. Higher ratios indicate stronger financial independence and lower leverage.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Equity Ratio's Biofrontera with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Biofrontera

All Key Metrics — Biofrontera